Economic burden of cancer does not stop after treatment
the ONA take:
According to a new study released online and being presented at the upcoming ASCO Annual Meeting in Chicago, IL, researchers have found that the economic burden of cancer extends into survivorship.
Specifically, cancer survivors deal with excess medical expenses, employment disability, and reduced production at work.
For the study, researchers analyzed the economic burden among elderly and nonelderly survivors with breast, colorectal, and prostate cancer in the United States using data from the Medical Expenditure Panel Survey between 2008 and 2012.
Researchers identified 1,568 female breast cancer survivors, 540 colorectal cancer survivors, and 1,170 prostate cancer survivors and compared their expenditures, productivity loss at work, and productivity loss at home to 100,000 people without a cancer history.
Results showed that elderly and nonelderly patients had between $9,278 and $20,238 of total annual economic burden depending on cancer type.
Nonelderly survivors of breast and colorectal cancer lost 3 and 7 days worth of productivity at work, respectively, and 3 and 5 days worth of productivity at home, respectively.
The economic burden of cancer extends into survivorship
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|